In Vivo Research

The IVIS^® Lumina Series III brings together years of leading optical imaging technologies into one easy to use and exquisitely sensitive bench-top system.

Industry leading Fluorescence, Bioluminescence and X-Ray Imaging - All-In-One benchtop instrument! The IVIS^® Lumina XRMS (x-ray multi-species optical imaging system) adds to the versatility of the IVIS Lumina XR by offering the flexibility to image large animals up to 500 grams with precise optical and X-Ray overlay.

The IVIS^® Lumina LT Series III pre-clinical in vivo imaging system offers the industries most sensitive benchtop platform at an entry level price.

The IVIS^® SpectrumCT preclinical in vivo imaging system expands upon the versatility of the IVIS Spectrum by offering 2D and 3D imaging capabilities but includes integrated low-dose microCT ideal for longitudinal studies. The system provides researchers with greater insights into complex biological systems by enabling simultaneous molecular and anatomical non-invasive imaging in animal models.

The FMT® 1000 is an entry level 3D fluorescence tomographic system with the ability to quantitate a single fluorophore at a time.

The IVIS^® Spectrum in vivo imaging system combines 2D optical and 3D optical tomography in one platform. The system uses leading optical technology for preclinical imaging research and development ideal for non-invasive longitudinal monitoring of disease progression, cell trafficking and gene expression patterns in living animals.

The IVIS® SpectrumBL is an advanced high-throughput 2D and 3D optical imaging system designed to improve quantitative outcomes of bioluminescent, chemiluminescent and Cerenkov in vivo imaging.

Image beyond bone – into oncology, cardiovascular and pulmonary diseases, and much more, with the Quantum GX2 microCT imaging system. With the Quantum GX2, flexibility is key. Combining the ability to perform high speed, low dose scans, ideal for longitudinal studies, across multiple species (mice, rats, rabbits) with high resolution ex vivo scanning, the Quantum GX2 microCT imaging system offers the flexibility and performance you need to not just image, but further understand your disease models.

Our bioluminescent light-producing oncology cell lines are labeled with luciferase or dual labeled with luciferase and fluorescent reporters (GFP) for in vivo studies.

Our bioluminescent light-producing oncology cell lines are labeled with luciferase or dual labeled with luciferase and fluorescent reporters (GFP) for in vivo studies.

Our bioluminescent light-producing oncology cell lines are labeled with luciferase or dual labeled with luciferase and fluorescent reporters (GFP) for in vivo studies.

Our bioluminescent light-producing oncology cell lines are labeled with luciferase or dual labeled with luciferase and fluorescent reporters (GFP) for in vivo studies.

Create the bioluminescent cell line you need.

Stably-transfect cells with prepackaged lentivirus particles expressing a combination of novel luciferases and a fluorescent protein for monitoring tumor growth, tracking primary or stem cells in vivo, and other applications.  

PerkinElmer’s RediFect^™ lentiviral particles contain Red-Fluc, the same red-shifted firefly luciferase (Luciola italica) as our Bioware^® Brite cell lines, for a stable bioluminescent signal excellent for deep tissue imaging; or use our green-shifted Renilla luciferase (Renilla reniformis) transgene. Both offer efficient transduction of a wide variety of mammalian cell lines including most cancer cell lines, primary, stem and non-dividing cells. Bioluminescent cells can be imaged using our luciferin or coelenterazine substrates.

Proteases perform a fundamental role in protein regulation. Altered activity of lysosomal cathepsins, a class of protease, can indicate many disease-related processes, such as those involved in cancer, inflammation, arthritis, cardiovascular and many others. The ability to detect and quantify normal as well as altered protease cathepsin activity in vivo allows the progress and severity of these disease states to be tracked and interrogated over time. PerkinElmer’s ProSense^® imaging agents are protease activatable NIR fluorescent probes that are optically silent in their intact state and become highly fluorescent following protease-mediated cleavage and activation. ProSense is available in 3 formats; 680, 750 EX, and 750 FAST.

Our bioluminescent light-producing oncology cell lines are labeled with luciferase or dual labeled with luciferase and fluorescent reporters (GFP) for in vivo studies.

Our bioluminescent light-producing oncology cell lines are labeled with luciferase or dual labeled with luciferase and fluorescent reporters (GFP) for in vivo studies.

Near-infrared (NIR) fluorescent agent for in vivo imaging and other applications.  

Integrins are a superfamily of transmembrane cell surface receptors that mediate signal transduction, cell-to-cell interaction, and cell-to-extracellular matrix adhesion - key processes for healthy cells as well as progression of disease states such as atherosclerosis and cancer, where integrins contribute to angiogenesis, tumorigenesis, and metastasis.

Among this superfamily, αvβ3 integrin holds promise as a therapeutic target in areas such as immuno-oncology, where αvβ3 integrin may prevent tumors from evading the immune system. PerkinElmer's IntegriSense^™ fluorescence probes are designed to target αvβ3 integrin for monitoring tumor growth, angiogenesis and assessing treatment efficacy.

Our bioluminescent light-producing oncology cell lines are labeled with luciferase or dual labeled with luciferase and fluorescent reporters (GFP) for in vivo studies.

Our bioluminescent light-producing oncology cell lines are labeled with luciferase or dual labeled with luciferase and fluorescent reporters (GFP) for in vivo studies.

XenoLight DiR NIR Fluorescent Dye can be used for non-invasive imaging of T-cell or stem cell homing in vivo. 

XenoLight RediJect 2-DeoxyGlucosone (DG) 750 is a fluorescent imaging probe for in vivo targeting of tumors that typically exhibit elevated glucose uptake rate in comparison to surrounding tissues. To achieve maximum glucose targeting and enhanced tumor uptake, the probe has been designed to contain four 2-DG molecules per dye molecule.  

Near-infrared (NIR) fluorescent agent for in vivo imaging and other applications. 

Near-infrared (NIR) fluorescent agent for in vivo imaging and other applications.  

Our bioluminescent light-producing oncology cell lines are labeled with luciferase or dual labeled with luciferase and fluorescent reporters (GFP) for in vivo studies.